<DOC>
	<DOCNO>NCT01832428</DOCNO>
	<brief_summary>This study single , centre trial study safety efficacy Bone marrow derive autologous MNCS ( 100 million per dose ) trial conduct 36 month stroke patient , primary outcome measure improvement muscle power Body face</brief_summary>
	<brief_title>A Clinical Trial Study Safety Efficacy Bone Marrow Derived Autologous Cell Treatment Stroke .</brief_title>
	<detailed_description>This study single centre trial study safety efficacy Bone marrow derive autologous MNCS ( 100 million per dose ) trial conduct 36 month stroke patient , primary outcome measure improvement muscle power Body face</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>Patient suffer stroke due cerebral infarct Haemorrhage accelerate hypertension . willingness undergo bone marrow derive autologous cell therapy . patient provide fully Informed consent form study . Ability willingness regular visit hospital follow protocol Procedure . Patients pre exist Current systemic disease lung , liver ( exception ; History uncomplicated Hepatitis A ) , gastrointestinal , Cardiac , Immunodeficiency , ( include HIV ) Or laboratory Investigation could cause neurological defect.History Life threating Allergic immune mediate reaction . Alcohol drug abuse / dependence . Severe skin infection . Haemodynamically unstable . subject primary secondary diabetes , Insulin depenence ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>